BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1585 related articles for article (PubMed ID: 25810047)

  • 1. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.
    Wells SA; Asa SL; Dralle H; Elisei R; Evans DB; Gagel RF; Lee N; Machens A; Moley JF; Pacini F; Raue F; Frank-Raue K; Robinson B; Rosenthal MS; Santoro M; Schlumberger M; Shah M; Waguespack SG;
    Thyroid; 2015 Jun; 25(6):567-610. PubMed ID: 25810047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidemiology and Clinical Presentation of Medullary Thyroid Carcinoma.
    Raue F; Frank-Raue K
    Recent Results Cancer Res; 2015; 204():61-90. PubMed ID: 26494384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical utility of genetic diagnosis for sporadic and hereditary medullary thyroid carcinoma.
    Elisei R; Bottici V; Cappagli V; Ramone T; Tacito A; Ciampi R; Romei C
    Ann Endocrinol (Paris); 2019 Jun; 80(3):187-190. PubMed ID: 31053251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RET Y791F Variant Does Not Increase the Risk for Medullary Thyroid Carcinoma.
    Toledo RA; Maciel RM; Erlic Z; Lourenço DM; Cerutti JM; Eng C; Neumann HP; Toledo SP
    Thyroid; 2015 Aug; 25(8):973-4. PubMed ID: 25950813
    [No Abstract]   [Full Text] [Related]  

  • 5. Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update.
    Wells SA; Pacini F; Robinson BG; Santoro M
    J Clin Endocrinol Metab; 2013 Aug; 98(8):3149-64. PubMed ID: 23744408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Management of multiple endocrine neoplasia syndrome type 2 families in association with rare germline mutations of the RET proto-oncogene].
    Fitze G; Saeger HD; Roesner D; Schackert HK
    Klin Padiatr; 2004; 216(5):270-6. PubMed ID: 15455293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple endocrine neoplasia type 2: recent progress in diagnosis and management.
    Heshmati HM; Hofbauer LC
    Eur J Endocrinol; 1997 Dec; 137(6):572-8. PubMed ID: 9437218
    [No Abstract]   [Full Text] [Related]  

  • 8. Multiple endocrine neoplasia type 2.
    Lodish M
    Front Horm Res; 2013; 41():16-29. PubMed ID: 23652668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Twenty years of lesson learning: how does the RET genetic screening test impact the clinical management of medullary thyroid cancer?
    Romei C; Tacito A; Molinaro E; Agate L; Bottici V; Viola D; Matrone A; Biagini A; Casella F; Ciampi R; Materazzi G; Miccoli P; Torregrossa L; Ugolini C; Basolo F; Vitti P; Elisei R
    Clin Endocrinol (Oxf); 2015 Jun; 82(6):892-9. PubMed ID: 25440022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer.
    Lodish MB; Stratakis CA
    Expert Rev Anticancer Ther; 2008 Apr; 8(4):625-32. PubMed ID: 18402529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic and surgical dilemmas in hereditary medullary thyroid carcinoma.
    Allen SM; Bodenner D; Suen JY; Richter GT
    Laryngoscope; 2009 Jul; 119(7):1303-11. PubMed ID: 19444888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sporadic and familial medullary thyroid carcinoma: state of the art.
    Moo-Young TA; Traugott AL; Moley JF
    Surg Clin North Am; 2009 Oct; 89(5):1193-204. PubMed ID: 19836492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular mechanisms of medullary thyroid carcinoma: current approaches in diagnosis and treatment.
    Boikos SA; Stratakis CA
    Histol Histopathol; 2008 Jan; 23(1):109-16. PubMed ID: 17952863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current understanding and management of medullary thyroid cancer.
    Roy M; Chen H; Sippel RS
    Oncologist; 2013; 18(10):1093-100. PubMed ID: 24037980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Multiple endocrine neoplasia type 2a and 2b].
    Vestergaard P
    Ugeskr Laeger; 1996 Jan; 158(5):590-3. PubMed ID: 8607216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hereditary medullary thyroid carcinoma syndromes: experience from western India.
    Diwaker C; Sarathi V; Jaiswal SK; Shah R; Deshmukh A; Thomas AE; Prakash G; Malhotra G; Patil V; Lila A; Shah N; Bandgar T
    Fam Cancer; 2021 Jul; 20(3):241-251. PubMed ID: 33392850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Germline RET mutation carriers in Japanese patients with apparently sporadic medullary thyroid carcinoma: A single institution experience.
    Kihara M; Miyauchi A; Yoshioka K; Oda H; Nakayama A; Sasai H; Yabuta T; Masuoka H; Higashiyama T; Fukushima M; Ito Y; Kobayashi K; Miya A
    Auris Nasus Larynx; 2016 Oct; 43(5):551-5. PubMed ID: 26837867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Multiple endocrine neoplasia type 2].
    Maia AL; Gross JL; Puñales MK
    Arq Bras Endocrinol Metabol; 2005 Oct; 49(5):725-34. PubMed ID: 16444355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple endocrine neoplasia type II and familial medullary thyroid carcinoma. Impact of genetic screening on management.
    Gagel RF
    Cancer Treat Res; 1997; 89():421-41. PubMed ID: 9204204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylactic thyroidectomies in MEN2 syndrome: Management and outcomes.
    Bussières V; Roy S; Deladoey J; Rousseau É; St-Vil D; Piché N
    J Pediatr Surg; 2018 Feb; 53(2):283-285. PubMed ID: 29336779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 80.